Efficacy and safety of second- or third-line nab-paclitaxel + durvalumab in patients with advanced NSCLC (ABOUND.2L+)

Ítems similars

• Quality of life in patients with advanced NSCLC treated in second- or third-line with nab-paclitaxel + durvalumab: abound.2l+
  per: Talbot, D, et al.
  Publicat: (2018)
• Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+
  per: Govindan, R, et al.
  Publicat: (2017)
• ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)
  per: Morgensztern, D, et al.
  Publicat: (2017)
• nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
  per: Daniel Morgensztern, et al.
  Publicat: (2021-02-01)
• Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer
  per: Ponce Aix, S, et al.
  Publicat: (2020)